Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 17/04/2026 pm IST			5-day change	1st Jan Change
329.30 ^DKK	+4.54%		+14.42%	-29.40%

14/04	Zealand Pharma A/S Announces the Appointment of Eric Rojas as Head of Investor Relations, Effective April 15, 2026	CI
26/03	Zealand Pharma A/S Approves Management Changes	CI

Cantor Fitzgerald Downgrades Zealand Pharma to Neutral (Overweight) - BN

Published on 03/06/2026 at 05:01 pm IST

Finwire - Translated by Marketscreener - See original

ZEALAND PHARMA A/S

+4.54%

Cantor Fitzgerald downgrades Zealand Pharma to neutral (overweight) - BN

Latest news about Zealand Pharma A/S

14/04	Zealand Pharma A/S Announces the Appointment of Eric Rojas as Head of Investor Relations, Effective April 15, 2026	CI
26/03	Zealand Pharma A/S Approves Management Changes	CI
26/03	Wolfe Research Starts Zealand Pharma with Outperform Rating	MT
26/03	Wolfe Research initiates coverage on Zealand Pharma with Outperform rating and DKK 750 price target - BN	FW
24/03	Danish Biotech Group Zealand Pharma to Open New Research Hub in US	MT
24/03	Zealand Pharma Establishes U.S. Research Hub in Cambridge Massachusetts	CI
20/03	Nykredit cuts Zealand Pharma price target to DKK 500 (650), reiterates Buy - BN	FW
20/03	Zealand Pharma Announces Share Capital Increase	MT
19/03	Danske Bank cuts Zealand Pharma price target to DKK 625 (770), reiterates Buy - BN	FW
16/03	Genentech CEO says aiming for tolerable, affordable obesity drugs	RE
12/03	Deutsche Bank cuts Zealand Pharma price target to DKK 275 (450), reiterates Hold	FW
12/03	Zealand Pharma A/S Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 02:00 PM
11/03	JP Morgan lowers price target for Zealand Pharma to 460 Danish kroner (1,000), reiterates overweight - BN	FW
10/03	Spago Nanomedical AB Appoints Torsten Malmström as Director CMC & Supply and Management Team Member	CI
09/03	U.S. Futures Down, European Stocks Fall	DJ

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.

Employees

491

Sector

Biotechnology & Medical Research

Calendar

07/05 - Earnings release - Q1 2026

More about the company